Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.85 |
| ▸ | FAAH | O00519 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.62 |
| ▸ | PRKCA | P17252 | 1/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.61 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.61 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.61 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.61 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glyceryl Monooleate SCHEMBL5998232 | 0.97 | DGKA (0.90) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL15995146 | 0.95 | DGKA (0.94) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL7756172 | 0.95 | DGKA (0.94) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL5608924 | 0.92 | DGKA (0.90) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL5158478 | 0.92 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL20719803 | 0.92 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL18970879 | 0.92 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| SCHEMBL20719744 | 0.92 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL1237693 | 0.92 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 | |
| Glyceryl Monooleate SCHEMBL4398941 | 0.92 | DGKA (1.00) | DGKAFAAHKDM4EDUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092428-A1 | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof | TRANSFORM PHARMACEUTICALS,INC. | 2004-05-13 | — | — | US | claimed |
| US-20100210027-A9 | METHOD FOR DETERMINING EFFECT OF PREFORMULATION FORMS ON THEIR DISSOLUTION RATES | TRANSFORM PHARMACEUTICALS, INC. | 2010-08-19 | — | — | US | disclosed |
| EP-1558931-B1 | ANALYSIS OF PHARMACEUTICAL SOLUBILITY AND STABILITY | TRANSFORM PHARMACEUTICALS INC (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060148877-A1 | Pharmaceutical formulations of celcoxib | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | US | disclosed |
| US-20060140985-A1 | Lansoprazole formulations and related processes and methods | TRANSFORM PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-20060057734-A1 | Preformulation analysis and optimization | TRANSFORM PHARMACEUTICALS, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20060004037-A1 | Novel tricyclic compounds and related methods of treatment | TRANSFORM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20040106098-A1 | Analysis of pharmaceutical solubility and stability | TRANSFORM PHARMACEUTICALS | 2004-06-03 | — | — | US | disclosed |
| US-20040092428-A1 | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof | TRANSFORM PHARMACEUTICALS,INC. | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060140985-A1 | Lansoprazole formulations and related processes and methods | SI, GIPR, RICTOR | DGKA 4139/4885FAAH 741/4885KDM4E 2970/4885 |
| US-20060004037-A1 | Novel tricyclic compounds and related methods of treatment | ABCC1, ABCB1, ABCC3 | DGKA 2029/4885FAAH 1932/4885KDM4E 4464/4885 |
| US-20040092428-A1 | Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof | ABCB11, ABCB1, ABCG2 | DGKA 3499/4885FAAH 2953/4885KDM4E 4288/4885 |
| US-20060148877-A1 | Pharmaceutical formulations of celcoxib | CBX2, CBX3, LPXN | DGKA 4724/4885FAAH 939/4885KDM4E 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.